Advertisement
Advertisement
REGN
Regeneron Pharmaceuticals Inc
785.39
USDSponsored
+18.76
+2.45%
Feb 06, 15:59 UTC -5
Closed
After-Market
784.84
-0.55
-0.07%
REGN Earnings Reports
Positive Surprise Ratio
REGN beat 33 of 40 last estimates.
83%
Next Report
Date of Next Report
Apr 27, 2026
Estimate for Q1 26 (Revenue/ EPS)
$3.52B
/$9.36
Implied change from Q4 25 (Revenue/ EPS)
-9.35%
/-18.18%
Implied change from Q1 25 (Revenue/ EPS)
+16.25%
/+13.87%
Regeneron Pharmaceuticals Inc earnings per share and revenue
On Jan 30, 2026, REGN reported earnings of 11.44 USD per share (EPS) for Q4 25, beating the estimate of 10.82 USD, resulting in a 5.65% surprise. Revenue reached 3.88 billion, compared to an expected 3.88 billion, with a 0.21% difference. The market reacted with a -1.07% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 11 analysts forecast an EPS of 9.36 USD, with revenue projected to reach 3.52 billion USD, implying an decrease of -18.18% EPS, and decrease of -9.35% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Regeneron Pharmaceuticals Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Regeneron Pharmaceuticals Inc reported EPS of $11.44, beating estimates by 5.65%, and revenue of $3.88B, 0.21% above expectations.
How did the market react to Regeneron Pharmaceuticals Inc's Q4 2025 earnings?
The stock price moved down -1.07%, changed from $749.44 before the earnings release to $741.45 the day after.
When is Regeneron Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for Apr 27, 2026.
What are the forecasts for Regeneron Pharmaceuticals Inc's next earnings report?
Based on 11
analysts, Regeneron Pharmaceuticals Inc is expected to report EPS of $9.36 and revenue of $3.52B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement